Form 4: Lilly Endowment Sells $86.8M in Eli Lilly Stock

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 113,694 shares of common stock for approximately $86.8 million on September 30, 2025.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), reported the sale of 113,694 shares of common stock.
• The transactions occurred on September 30, 2025, with shares sold at weighted average prices ranging from $763.095 to $766.117.
• The total value of the shares sold is approximately $86,794,979.
• Following these sales, Lilly Endowment Inc. directly holds 95,492,993 shares of Eli Lilly & Co. common stock.
• The sales were executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 4

Explanation: A significant shareholder, Lilly Endowment Inc., sold a substantial number of shares, which could be interpreted as a slight negative signal. However, the transaction was executed under a pre-arranged 10b5-1 plan, suggesting it is part of a planned portfolio rebalancing rather than a reaction to new information, thus mitigating strong negative sentiment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary sale.

Negatives

• Lilly Endowment Inc., a 10% owner, sold 113,694 shares of Eli Lilly & Co. common stock.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold 113,694 shares of common stock, constituting a related party transaction.

Stakeholder Impact

• Shareholders: The sale by a significant owner could lead to minor downward pressure on the stock price or be interpreted as a signal, though often these are routine rebalancing activities.

Key Dates

Keywords

Eli Lilly, LLY, Lilly Endowment, insider trading, Form 4, stock sale, beneficial ownership, 10b5-1 plan